Why STERIS Stock Is On Investors’ Radar Today
Without a specific news headline driving STERIS (STE) today, investors are refocusing on the company’s fundamentals, including its healthcare focused revenue mix and recent share price moves over the past year.
See our latest analysis for STERIS.
At a share price of US$210.03, STERIS has experienced softer short-term share price performance, with the 1-day move down 1.09% and the 90-day share price return declining 5.43%, while the 5-year total shareholder return of 11.04% reflects a steadier long-run outcome.
If you are comparing STERIS with other healthcare related opportunities, it can be useful to broaden your watchlist using the Simply Wall St screener for 39 healthcare AI stocks
With STERIS shares down over the past year, trading at around a 10% discount to one estimate of intrinsic value and roughly 22% below some analyst targets, should you view this as a mispricing or as a valuation that already reflects expectations for future growth?
Most Popular Narrative: 18.2% Undervalued
Compared with the last close at $210.03, the most followed narrative pegs STERIS at a higher fair value, built around its earnings and margin outlook.
Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards, supporting both revenue and margin expansion.
This raises the question of what kind of revenue mix and margin profile could justify that higher fair value, and what future earnings power analysts are incorporating into this narrative.
In this framework, the narrative uses a discount rate of 7.64%, assumes steady revenue growth and firmer profit margins, and applies a higher future P/E than the broader US Medical Equipment industry to arrive at an estimated fair value of $256.86.
Result: Fair Value of $256.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be challenged if rising tariffs compress margins, or if healthcare reimbursement pressures slow hospital capital spending and weigh on future orders.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Another Way To Look At STERIS’ Valuation
The fair value narrative points to STERIS trading below an estimated value of US$256.86, but the market pricing tells a different story. At a P/E of 26.2x, the stock trades above both peers at 21.9x and the US Medical Equipment industry at 25.3x, and also above a fair ratio of 22.9x. That premium suggests investors are already paying up for quality. The key question is whether the earnings outlook fully justifies paying more than both peers and the fair ratio.
For a closer look at how this kind of comparison can cut both ways, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around STERIS has you thinking, take a moment to review the numbers yourself and stress test the key assumptions. To see what investors are excited about right now, check out the 4 key rewards
Looking For More Investment Ideas?
Do not stop with a single stock view. Broaden your opportunity set with a few focused stock lists that can help you spot different kinds of potential.
- Target steadier potential by scanning companies that appear resilient, using the 63 resilient stocks with low risk scores.
- Hunt for companies with strong financial footing by working through the solid balance sheet and fundamentals stocks screener (46 results).
- Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com